Sorry, you need to enable JavaScript to visit this website.

Français    |    Text Size: A | A | A

Knowledge Bank

@ExpressRxCanada

1/2: #HepC antivirals & PCSK9 inhibitors for high cholesterol created huge financial concerns ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 14

Two therapy classes – antivirals for hepatitis C and PCSK9 inhibitors for high cholesterol – created huge financial concerns in 2015.

@ExpressRxCanada

2/2: W/ many new #specialtydrugs in the pipeline, impact on private payers is expected to continue ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 14

With many new specialty drugs in the pipeline, this critical level of impact on private plans is expected to continue. 

@ExpressRxCanada

#Specialtydrug claims made up about 30% of total drug spending, a figure that has doubled in 8 yrs. ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 13

The increasing use of high-cost specialty drugs had a significant impact on drug spending in 2015 and will continue to be a key driver in the future. The doubledigit year-over-year growth of specialty spending continued in 2015, with an overall trend of 18.6%. This is remarkable, as utilization remains low – specialty drugs made up only 2% of all claims.

 

@ExpressRxCanada

Rare disease class on the rise: 53% increase in spending ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 13

The overall trend in this class in 2015 was 53.13%, driven primarily by a 35.66% increase in spending and a 17.5% increase in utilization . Most of the drugs in this therapy class are enzyme or enzyme co-factor replacements and are the only pharmacologic therapies for the diseases that they treat.

@ExpressRxCanada

Approx. 47% of all #cancer drugs in dev’t are orals; 25% are non-orals self-admin’d ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 13

The continued shift to oral dosage forms and away from intravenous forms, which are administered in hospital, adds to the financial burden on plan sponsors. Approximately 47% of all cancer drugs in development are oral medications; another 25% are non-oral self-administration. 

@ExpressRxCanada

#Specialtydrug claims to continue to increase; Expected to reach 42% by 2020 ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 12

Of even greater concern, the share of total spending comprised of specialty medication claims continued to increase rapidly, to 29.9% from 26.5% in 2014. It is expected to reach 42% by 2020.

@ExpressRxCanada

1/2 :Era of blockbuster drug exclusivity is coming to an end with expected #patent expiries ow.ly/hsBM3008PAH  #DrugTrend15 #PBM

May 12

The era of blockbuster drugs losing market exclusivity as a result of patent expiries has come to an end. 

@ExpressRxCanada

2/2: Savings & impact on use of #generics is lower than in previous years ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 12

There were first-time generics approved in 2015, but they were not widely used. As a result, anticipated savings and impact on the use of generics is lower than in previous years. 

@ExpressRxCanada

16% of total spending was for new, brand-name drugs that were app’d in the last 5 yrs ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 12

Express Scripts Canada research shows that 16% of total spending in 2015 was for new, brand-name drugs that received Health Canada approvals between 2010 and 2015.

@ExpressRxCanada

Health Canada expanded approved indications for many medications in 2015, leading to increased use. ow.ly/hsBM3008PAH

May 12

This phenomenon appears to be more common among specialty drugs for the treatment of cancer and in ammatory conditions.

@ExpressRxCanada

7k potential drugs in dev’t for oncology, neuro disorders & infectious diseases–all high-use classes ow.ly/hsBM3008PAH #DrugTrend15

May 11

One of the challenges threatening the sustainability of the pharmacy benefit is inflationary pressure from new high-cost medications for a variety of diseases. New drug approvals and the development pipelines continue to be dominated by the specialty category.

@ExpressRxCanada

1/2: 1 in 5 private plan members have 4+ conditions ow.ly/hsBM3008PAH
#DrugTrend15 #PBM

May 11

Our extensive analysis of claim patterns reveals that over half of plan members suffer from multiple chronic conditions. Furthermore, we found that one in every five claimants suffers from four or more chronic disease states at once. 

@ExpressRxCanada

2/2: Patients waste an avg. $436/year due to uninformed drug & pharmacy choices on meds ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 11

These patients submit an average of 36 claims per year and represent over half of total spending (53%). Their average annual per patient spending was $2,296 in 2015, 4.7 times that of other claimants.

@ExpressRxCanada

Patients w/ chronic & complex conditions ^ from 15.3% to 19.5% in 2015 ow.ly/nEKz3006qP0  #DrugTrend15 #PBM

May 11

Our data analysis shows the incidence of patients with increasing from 15.3% of all claimants in 2010 to 19.5% in 2015.  Overall utilization by these patients has also grown, from 45.6% of total claims in 2010 to 52.2% of total claims in 2015.

@ExpressRxCanada

Costly new drugs for common conditions like high #cholesterol will drive drug spending in 2016+ ow.ly/hsBM3008PAH #DrugTrend15 #PBM

May 11

New high-cost drugs for common conditions such as high cholesterol have been introduced and are expected to drive greater spending increases in this category in 2016 and onward. 

@ExpressRxCanada

All provinces except #Saskatchewan had trend increases in 2015 (from 1.6% to 5.9%) ow.ly/hsBM3008PAH 
#DrugTrend15 #PBM

May 10

A significant change in direction compared to 2014, when six of the ten provinces had trend declines. This is a strong signal that the impact of recent provincial reforms is at an end, and the impact of new, higher-cost brands is once again the predominant influence on the drug trend.

@ExpressRxCanada

1/2: About 72% of #cancer drugs in dev’t don’t have to be admin'd in hospital #DrugTrend15 #PBM ow.ly/hsBM3008PAH

May 10

The continued shift to oral dosage forms and away from intravenous forms, which are administered in hospital, adds to the financial burden of plan sponsors.

@ExpressRxCanada

2/2: This trend shifts costs to private plan sponsors. ow.ly/hsBM3008PAH
#Specialitydrug #PBM #DrugTrend15

May 10

The continued shift to oral dosage forms and away from intravenous forms, which are administered in hospital, adds to the financial burden of plan sponsors.

Express Scripts Canada